Open AccessPhosphodiesterase type 5 inhibitor (Levitra): possibility of correction of erectile dysfunction in obese patients
Author(s) -
Alina Popova,
Л. В. Кондратьева,
А С Аметов
Publication year - 2008
Publication title -
ožirenie i metabolizm
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.154
H-Index - 5
eISSN - 2306-5524
pISSN - 2071-8713
DOI - 10.14341/omet2008124-29
Subject(s) - erectile dysfunction , medicine , obesity , type 2 diabetes , diabetes mellitus , cgmp specific phosphodiesterase type 5 , disease , metabolic syndrome , cancer , heart disease , endocrinology
Obesity is the cause of a number of diseases such as type 2 diabetes, hypertension, atherosclerosis and coronary heart disease [1]. Obesity is associated with the development of a number of hormone-dependent tumors (breast cancer, uterine cancer) and colon cancer [2]. Metabolic and hormonal disorders that accompany obesity and underlying a number of diseases, including may have an impact on erectile function. Despite the fact that in the literature there are few publications on the relationship of obesity and erectile dysfunction (ED), we could not find work on the effectiveness of treatment of patients with erectile dysfunction and obesity. These large-scale research on the role of weight loss in the treatment of other diseases, such as such as type 2 diabetes, hypertension, coronary heart disease, suggest that weight control and related metabolic disorders are able to provide a significant improvement in erectile quality function and effectiveness of the treatment of ED [3, 4, 5, 6].